SCHEMBL106543

SCHEMBL106543

CC(C)CC(=O)C(O)Cc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANPEP P15144 1/20 0.49
RNPEP Q9H4A4 1/20 0.49
DNPEP Q9ULA0 1/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
CYP1A2 P05177 1/20 0.47
TRPA1 O75762 3/20 0.46
CPA1 P15085 2/20 0.46
CPB1 P15086 1/20 0.46
CPA3 P15088 1/20 0.46
CPB2 Q96IY4 1/20 0.46
PSMB5 P28074 1/20 0.45
ALPI P09923 1/20 0.44
PKM P14618 1/20 0.44
PTGS1 P23219 1/20 0.44
XIAP P98170 1/20 0.44
SLC7A5 Q01650 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30433920 1.00 ANPEP (0.49) ANPEPRNPEPDNPEPNPC1RAB9A
SCHEMBL107420 0.84 TAAR1 (0.48) SLC7A5SLC6A2TAAR1
SCHEMBL9579765 0.83 HPGD (0.53) ANPEPRNPEPDNPEPNPC1RAB9A
SCHEMBL8919717 0.81 CYP1A2 (0.50) NPC1RAB9ACYP1A2TRPA1CPA1
SCHEMBL8380411 0.81 CYP1A2 (0.50) NPC1RAB9ACYP1A2TRPA1CPA1
SCHEMBL109575 0.81 CYP1A2 (0.50) NPC1RAB9ACYP1A2TRPA1CPA1
SCHEMBL28186887 0.79 CYP1A2 (0.52) NPC1RAB9ACYP1A2TRPA1CPA1
SCHEMBL454095 0.79 CES2 (0.52) CYP1A2TRPA1CPA1CPB1CPA3
SCHEMBL13176789 0.78 ALDH1A1 (0.50) ANPEPCYP1A2ALDH1A1HPGDKMT2A
SCHEMBL6121990 0.78 CYP1A2 (0.47) NPC1RAB9ACYP1A2TRPA1CPA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463374-A2 Isolated alcohol dehydrogenase enzymes and uses thereof Bio Architecture Lab, Inc. (US) 2012-06-13 EP claimed
EP-2195440-A2 BIOFUEL PRODUCTION Bio Architecture Lab, Inc. (US) 2010-06-16 EP claimed
US-20090155873-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-18 US claimed
US-20090139134-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-04 US claimed
WO-2009046375-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO claimed
WO-2009046370-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO claimed
EP-3230463-B2 RAPID PRETREATMENT APALTA PATENTS OUE (EE) 2025-07-16 EP disclosed
US-20240425893-A1 RAPID PRETREATMENT Apalta Patents OÜ (EE) 2024-12-26 US disclosed
US-12054761-B2 Rapid pretreatment Apalta Patents OÜ (EE) 2024-08-06 US disclosed
CN-117740961-A Compound analysis method of liquorice and liquorice probiotics fermentation preparation 北京中医药大学 2024-03-22 CN disclosed
US-11821047-B2 High pressure zone formation for pretreatment Apalta Patent OÜ (EE) 2023-11-21 US disclosed
US-20230295678-A1 RAPID PRETREATMENT Apalta Patents OÜ (EE) 2023-09-21 US disclosed
EP-4098750-A1 RAPID PRETREATMENT Sweetwater Energy, Inc. (US) 2022-12-07 EP disclosed
US-20100086981-A1 COMPOSITIONS AND METHODS FOR IMPROVED SACCHARIFICATION OF BIOMASS QTEROS, INC. (US) 2010-04-08 US disclosed
US-20090203089-A1 ISOLATED ALCOHOL DEHYDROGENASE ENZYMES AND USES THEREOF BIO ARCHITECTURE LAB, INC. (US) 2009-08-13 US disclosed
WO-2009097346-A2 ISOLATED ALCOHOL DEHYDROGENASE ENZYMES AND USES THEREOF BIO ARCHITECTURE LAB, INC. (US) 2009-08-06 WO disclosed
US-20090155873-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-18 US disclosed
US-20090139134-A1 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-06-04 US disclosed
WO-2009046375-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO disclosed
WO-2009046370-A2 BIOFUEL PRODUCTION BIO ARCHITECTURE LAB, INC. (US) 2009-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090139134-A1 BIOFUEL PRODUCTION MGAM, DCXR, MANBA ANPEP 481/4885RNPEP 279/4885DNPEP 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.